NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Individuals Who Provided Content Development and/or Authorship Assistance

The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.

Leo I. Gordon, MD, Panel Vice Chair
Mary A. Dwyer, MS, CGC, Senior Director, Guidelines Coordinator, NCCN
Hema Sundar, PhD, Senior Director, Global Clinical Content, NCCN

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Andrew D. Zelenetz, MD, PhD, Panel Chair, has disclosed serving as a consultant for AbbVie, Inc., Amgen Inc., Arvinas, AstraZeneca Pharmaceuticals LP, BeiGene, Bristol Myers Squibb, Eli Lilly and Company, Genentech, Inc., Gilead Sciences, Inc., Janssen Pharmaceutica Products, LP, MEI Pharma Inc., MorphoSys AG, Novartis Pharmaceuticals Corporation, and Roche Laboratories, Inc.; serving as a scientific advisor for Adaptive Biotechnologies, ADC Therapeutics, Arvinas, and Eli Lilly and Company; and receiving grant/research support from BeiGene, Genentech, Inc., MEI Pharma Inc., and Roche Laboratories, Inc.
L. Elizabeth Budde, MD, PhD, Panel Member, has disclosed serving as a consultant for AbbVie, Inc., ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Kite Pharma, and Roche Laboratories, Inc.; and receiving grant/research support from Amgen Inc., AstraZeneca Pharmaceuticals LP, Merck & Co., Inc., and Mustang Bio, Inc.
Boyu Hu, MD, Panel Member, has disclosed receiving grant/research support from Artiva Biotherapeutics, AstraZeneca Pharmaceuticals LP, Caribou Biosciences, Celgene Corporation, CRISPR Therapeutics, Genentech, Inc., MorphoSys AG, Newave Pharmaceutical Inc., and Repare Therapeutics Inc.; and serving as a consultant for ADC Therapeutics, Bristol Myers Squibb, Eli Lilly and Company, GenMab, ImmPACT Bio, Novartis Pharmaceuticals Corporation, and SeaGen.
Ann S. LaCasce, MD, MMSc, Panel Member, has disclosed serving as a consultant for Kite Pharma and SeaGen.
Praveen Ramakrishnan, MD, MS, Panel Member, has disclosed serving as a consultant for ADC Therapeutics, Bristol Myers Squibb, Cellectar Biosciences, Inc., Ipsen, Kite Pharma, Ono Pharmaceutical Co., Ltd., Pharmacyclics, and Rafael Pharmaceuticals, Inc./Cornerstone Pharmaceuticals; and receiving honoraria from ADC Therapeutics, Cellectar Biosciences, Ipsen, Ono Pharmaceutical Co., Ltd., and Pharmacyclics.
Erin Reid, MD, Panel Member, has disclosed receiving grant/research support from ADC Therapeutics, Aptose Biosciences Inc., and Millennium Pharmaceuticals, Inc.
Stephen D. Smith, MD, Panel Member, has received grant/research support from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare, BeiGene, Bristol Myers Squibb, DeNovo Biopharma, Enterome, Genentech, Inc., Incyte Corporation, Kymera Therapeutics, Merck & Co., Inc., MorphoSys AG, Nanjing Pharmaceuticals, and Viracta Therapeutics; and serving as a consultant for AbbVie, Inc., ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene, Genentech, Inc., Incyte Corporation, Karyopharm Therapeutics, Kite Pharma, and Numab Therapeutics.
Jakub Svoboda, MD, Panel Member, has disclosed receiving grant/research support from Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Incyte Corporation, Merck & Co., Inc., Pharmacyclics, and TG Therapeutics, Inc.; and served as a consultant for Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP, Atara Biotherapeutics, Bristol Myers Squibb, Incyte Corporation, and Pharmacyclics.
Lode J. Swinnen, MB, ChB, Panel Member, has disclosed receiving grant/research support from AbbVie, Inc.
Joseph Tuscano, MD, Panel Member, has disclosed receiving grant/research support from AbbVie, Inc., ADC Therapeutics, Bristol Myers Squibb, Genentech, Inc., Pharmacyclics, and SeaGen.
Julie M. Vose, MD, MBA, Panel Member, has disclosed receiving honoraria from AbbVie, Inc., AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, and MEI Pharma Inc.

View all of the conflicts of interest for the NCCN Guidelines panel

NCCN Staff Disclosures

None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.